Eastern Virginia Medical School Study Indicates Major Glycemic Improvement in Subcutaneous Basal Bolus Insulin Delivery Using eGlycemic Management System

MAY 13, 2014

Eastern Virginia Medical School Study Indicates Major Glycemic Improvement in Subcutaneous Basal Bolus Insulin Delivery Using eGlycemic Management System

Poster presented during AACE shows improved outcomes using Glytec’s subcutaneous insulin dosing solution versus traditional basal bolus insulin therapy.

Greenville, SC — Glytec, a clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control, is pleased to share the results of a late-breaking poster that was presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress. The poster is based on results experienced by Sentara Healthcare during the first 30 days after using Glytec’s Glucommander™ SubQ to manage subcutaneous basal bolus insulin (BBI) therapy. The poster was presented by Joseph Aloi, MD, clinical director of the Strelitz Diabetes Center at Eastern Virginia Medical School, during the Congress’s general poster session.

Researchers studied the glycemic impact of Sentara’s use of Glucommander SubQ, part of Glytec’s eGlycemic Management System® (eGMS®), for the treatment of patients with hyperglycemia in comparison to traditional BBI protocols alone over a 30-day time period. Use of Glucommander SubQ to treat hyperglycemia in patients on subcutaneous insulin showed reductions in hypoglycemia in the first 30 days of use and two times the hyperglycemic improvement compared to traditional basal bolus treatment orders. Baseline hypoglycemia episodes (blood sugar <70 mg/dL) were reduced by 28 percent with the eGMS compared to BBI during the study, and patients with hyperglycemia experienced a 30 percent reduction in blood glucose between admission and discharge, twice the improvement seen in patients receiving traditional BBI therapy alone.

“Hyperglycemia in hospitalized patients is a common, serious and costly health care problem and can have profound medical consequences, such as increased morbidity and mortality and longer hospitalization. Therefore, it is important that blood glucose levels in hospitalized patients be properly controlled,” says Dr. Joseph Aloi, lead author of the poster and chairman of Sentara’s Glycemic Control Committee. “These results are landmark in that Sentara already had better than average outcomes. To be able to save physicians’ time, improve patient care, modify organization-wide practice patterns and achieve numbers like this in such a short time period is indicative of the strength of Glytec’s system.”

Sentara previously implemented Glytec’s Glucommander IV, another solution within the eGMS. They experienced dramatically lowered rates for both hyperglycemia and hypoglycemia while managing IV insulin delivery with Glucommander and, based upon such, successfully expanded its use to all critical care units in eight of their hospitals thus far.

Sentara recognized, however, that managing subcutaneous insulin therapy on the non-critical care areas remained a challenge for the organization. Specifically, Sentara found that with their traditional processes, it was especially difficult to manage the meal-to-meal basal bolus insulin dose adjustments that are necessary to keep individuals on subcutaneous insulin within normal glycemic range. Clinical leadership believed that hard-wiring a complete system, including a computerized, cloud-based solution for managing BBI, and standardizing it across all hospital units would lead to improved outcomes. With this in mind, Sentara expanded their relationship with Glytec to include Glucommander SubQ. It was quickly implemented at two hospitals in southeast Virginia, one of which had already experienced long term success with Glytec’s IV solution, and it has since been deployed to six additional hospitals within the Sentara Healthcare system.

“Hospitals are faced with myriad challenges when it comes to inpatient glycemic management,” Aloi continues. “In our experience, the deployment of the entire Glytec eGMS suite of solutions, coupled with hospital-wide standardization, produces the best outcomes for the treatment of hyperglycemia and hypoglycemia compared to other methods and protocols currently in use in our nation’s healthcare facilities. The fully integrated system ensures correct insulin dosing throughout the entire hospital, not just in critical care areas, while simplifying the process for clinicians charged with patient blood glucose management.”

The Glytec eGlycemic Management System is a comprehensive, integrated glycemic management and surveillance system. Glytec has the only FDA-cleared algorithms for IV, subcutaneous and pediatric insulin dosing. The cloud-based system seamlessly integrates with leading EMRs and includes advanced clinical and business intelligence analytics and real-time surveillance capabilities. “We were fortunate to partner with an organization as forward-thinking as Sentara for this study,” says Raymie McFarland, Vice President of Quality Initiatives for Glytec. “We’re pleased with the results that Sentara has achieved with the eGMS and were excited to present these significant findings during AACE. Year after year, this event has proven to be a key opportunity to share with and learn from our peers in the industry.”